Novartis (NYSE:NVS) and MSN Pharmaceuticals have reached agreement in a Delaware federal court to dismiss patent litigation ...
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
As Trump appointee and vaccine skeptic RFK Jr. looks toward Washington, Novartis (NVS) CEO Vas Narasimhan is concerned about ...
SALES FORECAST: Novartis's sales are forecast at $12.78 billion, according to analysts' estimates compiled by Visible Alpha. This compares with $11.42 billion the year before. Shares rose 5.1% over ...
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...
In Novartis Pharms. Corp. v. Torrent Pharma Inc., the U. S. Court of Appeals for the Federal Circuit shut down efforts to market a generic version of the heart disease drug ENTRESTO which is sold ...
Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.
Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...
Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...